Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

NCT06708858 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Advanced Biliary Tract Cancer

Interventions

DRUG: Surufatinib
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Durvalumab
DRUG: Pembrolizumab

Sponsor

Dai, Guanghai